Bispecifics in Relapsed/ Refractory Multiple Myeloma: Combination Strategies, Stepping Up, and Treatment Dose Considerations
Panelists discuss the rationale behind combination strategies with bispecifics in relapsed/refractory multiple myeloma (R/R MM), highlighting key studies such as RedirecTT-1 for teclistamab and talquetamab, TRIMM-2 for talquetamab and daratumumab, and MagnetisMM-32 for elranatamab, along with considerations for step-up dosing and outpatient administration protocols.
Video content above is prompted by the following:
Let’s transition to recent updates on combination strategies with bispecifics in R/R MM: What is the rationale for these combination approaches?
- RedirecTT-1 for teclistamab andtalquetamab in R/R MM (Cohen et al. IMS 2024. Abstract OA-03/Cohen Y, J Clin Oncol 2023)
- TRIMM-2 for talquetamab anddaratumumab in R/R MM (Bahlis et al. IMS 2024. Abstract OA-01. /Dholaria B, J Clin Oncol 2023)
- MagnetisMM-32 for elranatamab vs EPd, PVd or Kd (Steven Schuster et al, ASCO 2024 Abstract TPS7576)
- How are the step-up and treatment doses for bispecifics administered at your institution? Are they administered in your clinic or in the community?
- How are patients monitored for cytokine release syndrome and immune cell-associated neurotoxicity syndrome during step-up dosing?
- Please comment on the following studies examining outpatient administration of bispecifics and how these strategies might be incorporated in practice:
- OPTec: Outpatient Step-Up Administration of Teclistamab
- Ambulatory Teclistamab Administration in R/R MM
- What does the process look like for step-up dosing, treatment doses, and monitoring? Are there any variations?
Recent Videos
Related Content
